Protocol for a randomised, double‐blind, placebo‐controlled study of grass allergen immunotherapy tablet for seasonal allergic rhinitis: time course of nasal, cutaneous and immunological outcomes
Authors:
- Esther Helen StevelingESEsther Helen Steveling
- Mongkol Lao‐ArayaMLMongkol Lao‐Araya
- Christopher KouliasCKChristopher Koulias
- Guy ScaddingGSGuy Scadding
- Aarif EifanAEAarif Eifan
- Louisa K. JamesLJLouisa K. James
- Alina DumitruADAlina Dumitru
- Martin PenagosMPMartin Penagos
- Moisés CalderónMCMoisés Calderón
- Peter Sejer AndersenPAPeter Sejer Andersen
- Mohamed ShamjiMSMohamed Shamji
- Stephen R. DurhamSDStephen R. Durham
Open Access
- 1 January 2015
- journal article
- research article
- Published by Wiley in Clinical and Translational Allergy
- Vol. 5 (1) , 1-12
Abstract
Background: Seasonal Allergic Rhinitis is characterised by inflammation of the nasal mucosa upon exposure to common aeroallergens, affecting up to 20–25 % of the population. For those patients whose symptoms are not controlled by standard medical treatment, allergen specific immunotherapy is a therapeutic alternative. Although several studies have shown changes in immunologic responses as well as long term tolerance following treatment with a sublingual allergy immunotherapy tablet, a detailed time course of the early mechanistic changes of local and systemic T and B cell responses and the effects on B cell repertoire in the nasal mucosa have not been fully examined.Methods/design: This is a randomized, double‐blind, single‐centre, placebo controlled, two arm time course study based in the United Kingdom comparing sublingual allergy immunotherapy tablet (GRAZAX®, ALK‐Abello Horsholm, Denmark) plus standard treatment with placebo plus standard treatment. Up to 50 moderate to severe grass pollen allergic participants will be enrolled to ensure randomisation of at least 44. Further, we shall enrol 20 non‐atopic volunteers. Screening will be completed before eligible atopic participants are randomised to one of the two treatment arms in a 1 to 1 ratio. The primary endpoint will be the total nasal symptom score assessed over 60 min following grass pollen nasal allergen challenge after 12 months of treatment. Clinical assessments and/or mechanistic analyses on blood, nasal fluid, brushing and biopsies will be performed at baseline at 1, 2, 3, 4 (coinciding with the peak pollen season), 6 and 12 months of treatment. After 12 months of treatment, unblinding will take place. Those atopic participants receiving active treatment will continue therapy for another 12 months followed by a post treatment phase of 12 months. Assessments and collection of biologic samples from these participants will take place again at 24 and at 36 months from the start of treatment. The 20 healthy, non‐atopic controls will undergo screening and one visit only coinciding with the 12 month visit for the atopic participants.Discussion: The trial will end in April 2017. The trial is registered with ClinicalTrials.gov and the trial identifying number is NCT02005627.Trial registration: Primary Registry: ClinicalTrials.gov, Trial Identifying number: NCT02005627, Secondary identifying numbers: EudraCT number: 2013‐003732‐72 REC: 13/EM/0351, Imperial College London (Sponsor): 13IC0847, Protocol Version 6.0, Date: 16.05.2014Keywords
Funding Information
- Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung
- Wellcome Trust (09788/Z/11/Z)
- EAACI (Research Fellowship)
- ALK Abello
This publication has 37 references indexed in Scilit:
- Aberrant dendritic cell function conditions Th2‐cell polarization in allergic rhinitisAllergy, 2013
- SQ-standardized sublingual grass immunotherapy: Confirmation of disease modification 2 years after 3 years of treatment in a randomized trialJournal of Allergy and Clinical Immunology, 2012
- Mechanisms of immunotherapy to aeroallergensClinical & Experimental Allergy, 2011
- Immunological Effects of Sublingual Immunotherapy: Clinical Efficacy Is Associated with Modulation of Programmed Cell Death Ligand 1, IL-10, and IgG4The Journal of Immunology, 2010
- Sustained effect of SQ‐standardized grass allergy immunotherapy tablet on rhinoconjunctivitis quality of lifeAllergy, 2010
- Nuocytes represent a new innate effector leukocyte that mediates type-2 immunityNature, 2010
- Sub‐lingual Immunotherapy: World Allergy Organization Position Paper 2009Allergy, 2009
- Inhibition of rBet v 1‐induced basophil histamine release with specific immunotherapy ‐induced serum immunoglobulin G: no evidence that FcγRIIB signalling is importantClinical & Experimental Allergy, 2006
- IL‐10 and TGF‐β cooperate in the regulatory T cell response to mucosal allergens in normal immunity and specific immunotherapyEuropean Journal of Immunology, 2003
- Allergen Immunotherapy: Therapeutic Vaccines for Allergic DiseasesAnnals of Allergy, Asthma & Immunology, 1998